Invesco Dynamic Biotechnology & Genome ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1Y SHOWN · NET +$87M OVER THIS RANGE
Money keeps arriving — +$90M of net buying over the past month, about 22.6% of the fund's asset base, while the price has returned +18.5% so far this year. At 0.58% a year it is not the cheapest way in — IBRN runs the same ground at 0.47%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS TODAY’S MOVE · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | REGNREGENERON PHARMACEUTICALS | 5.50% | $834.04 | +0.9% | ||
| 2 | AMGNAMGEN | 5.44% | $439.33 | +1.3% | ||
| 3 | VRTXVERTEX PHARMACEUTICALS | 5.24% | $548.05 | +1.4% | ||
| 4 | CDNACAREDX | 5.02% | $48.61 | +3.4% | ||
| 5 | RPRXROYALTY PHARMA | 4.76% | $61.31 | +1.2% | ||
| 6 | BIIBBIOGEN | 4.68% | $216.78 | +1.1% | ||
| 7 | GILDGILEAD SCIENCES | 4.53% | $146.12 | +1.9% | ||
| 8 | OMEROMEROS | 3.68% | $19.27 | +3.4% | ||
| 9 | UTHRUNITED THERAPEUTICS | 3.79% | $513.12 | -1.5% | ||
| 10 | HALOHALOZYME THERAPEUTICS | 3.55% | $108.17 | +1.9% | ||
| 11 | RGENREPLIGEN | 3.60% | $181.13 | +0.5% | ||
| 12 | PTGXPROTAGONIST THERAPEUTICS | 3.47% | $154.32 | +2.4% | ||
| 13 | ILMNILLUMINA | 3.38% | $219.40 | +2.9% | ||
| 14 | TECHBIO-TECHNE | 3.47% | $72.32 | +0.1% | ||
| 15 | ALNYALNYLAM PHARMACEUTICALS | 3.27% | $236.22 | +3.0% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 31| 1 week | +4.1% |
| 1 month | +8.5% |
| 3 months | +18.8% |
| 6 months | +18.5% |
| YTD | +18.5% |
| 1 year | +41.8% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | +$4M |
| 1 month | +$90M |
| 3 months | +$95M |
| YTD | +$92M |
| 1 year | +$87M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 5.5% of the book; the top ten carry 46%. Spread across 32+ names, it behaves like roughly 27 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| AMGN AMGEN | $6M | $5M |
| ALNY ALNYLAM PHARMACEUTICALS | $3M | $3M |
| NBIX NEUROCRINE BIOSCIENCES | $1M | $4M |
| VRTX VERTEX PHARMACEUTICALS | $1M | $3M |
| REGN REGENERON PHARMACEUTICALS | $2M | $963,854 |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat PBE on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.03% | $97.9B | +$245M | -55bp on fee · 246× the assets · +$245M in over the month | Head-to-head |
| IUSG iShares Core S&P U.S. Growth ETF | 0.04% | $33.8B | +$668M | -54bp on fee · 85× the assets · +$668M in over the month | Head-to-head |
| IUSV iShares Core S&P U.S. Value ETF | 0.04% | $28.1B | +$103M | -54bp on fee · 71× the assets · +$103M in over the month | Head-to-head |
| IVV iShares Core S&P 500 ETF | 0.03% | $900.9B | −$14.2B | -55bp on fee · 2265× the assets | Head-to-head |
| VOO Vanguard 500 Index Fund | 0.03% | $500.4B | — | -55bp on fee · 1258× the assets | Head-to-head |